![omniplan vs merlin omniplan vs merlin](https://www.conceptdraw.com/How-To-Guide/picture/multi-project-schedule-mac4.png)
A view into the future when the internal and external marketplace for services could be viewed and selected under the same portal.Īssaydepot, bioassaylink, LabNews, biopharmarket, contractlaboratory, gobalto, pharmeraid Services include molecular profiling, assays, assay development, compound synthesis, analysis, DMPK, toxicology, etc. Exploitation of the virtual R&D model is shown in programmes involving DNA inhibitors and cell signalling amongst others.ĭr Andrew McElroy, Pfizer – The evolving scientific services marketplace: new ways of operating / changing cost structure / outsourcing internallyĪ tour around marketplace websites (some listed below) who aim to match up service providers with customers. Mr Stuart Travers, Sentinel Oncology Ltd – Drug discovery virtualisation: an attractive prospectĭescription of how Sentinel are making use of efficiencies in the virtualisation of pharma R&D to enable the aggressive development of multiple R&D programmes. View from a successful CRO how Argenta have grown from contract compound supplier, tapping into the growing experience of their staff, to a high quality drug discovery outsourcing option. Contracts have moved from limited work with reference compounds to complex risk-sharing collaborations encompassing all aspects of drug discovery and development.ĭr Jeremy Billson, Argenta – Discovery outsourcing in the UK Focus on the vision of the founders, how the business has grown and the culture within the company and its employees.ĭr Jon Wright, BioDuro – From western pharma to Asian CRO – lessons learned during three years of establishing drug discovery in ChinaĬomprehensive presentation around the relationships between western pharma and Asian CROs and how this has developed over the last decade.
![omniplan vs merlin omniplan vs merlin](https://www.omnigroup.com/assets/img/2020/plan-20.jpg)
Mr Sunil Shah, O2h – Setting up a chemistry services business in India from scratch – the entrepeneur’s viewĮxciting presentation describing the 5 year story of the set up of a chemistry CRO and the building of state-of-the-art 300 fume-hood facilities in Ahmedabad, Northern India. Key findings including the issues of IT information flow & security between AZ and CROs.ĭr Stephen Shuttleworth, Karus Therapeutics – Small molecule lead discovery, optimization and development in a semi-virtual R&D environmentįascinating presentation on the activities of Karus Therapeutics and how, by adopting a semi-virtual model of drugs dicovery and development, the company has HDAC and PI3K inhibitors in a unique NCE pipeline from which the best will enter Phase I studies in 2010/11. The emergence of new CROs in Asia and Eastern Europe providing high quality, low cost services and how GSK will harness these services, focussing on the discovery of new medicines.ĭr Luigi La Vecchia, Novartis – Discovery chemistry outsourcing: optimising the processĪ detailed and comprehensive study on how Novartis established a small global network of preferred external suppliers for preparative scale synthesis with emphasis on the human element and how the experience has helped both Novartis and the CROs.ĭr Andy Morley, AstraZeneca – Lead identification – integrated outsourcingĭescription of how AZ has outsourced work with several CROs for chemical design, synthesis and physiochemical/assay/DMPK screening.
![omniplan vs merlin omniplan vs merlin](https://www.omnigroup.com/images/blog_images/standardipad.jpg)
The organisers had arranged a great programme of speakers from big pharma to virtual R&D companies, service providers and CROs.ĭr Alan Moodie, GSK – Drug Discovery outsourcing – a strategic choiceĪ good talk to start the day, setting the scene for how large pharma view the outsourcing situation with an emphasis on the GSK strategic (i.e.
![omniplan vs merlin omniplan vs merlin](https://a.fsdn.com/con/app/proj/merlin-project1.s/screenshots/mindmap_en.png)
I attended the Society of Chemical Industry‘s one day conference on the bang-up-to-date topic of Drug Discovery Outsourcing.